← Back to Analyst Consensus 
SGP Buy
SpyGlass Pharma, Inc.
Current Price —
Implied Upside —
Analysts 10
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 2 reiterations from 1 firms
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 21, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Oct 5, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Aug 14, 2026 | Raymond James | initiate | — → Outperform | — | 54% |
| Mar 10, 2026 | HC Wainwright & Co. | initiate | — → Buy | — | 44% |
| Mar 3, 2026 | Citigroup | initiate | — → Buy | — | 54% |
| Mar 3, 2026 | Leerink Partners | initiate | — → Outperform | — | 51% |
| Mar 3, 2026 | Jefferies | initiate | — → Buy | — | 52% |
| Mar 3, 2026 | Stifel | initiate | — → Buy | — | 53% |
Price Target Trend
Jun 28, 2026 Latest: $44 Oct 25, 2026
EPS Estimates
0q $-0.62
Lo: $-0.71 Hi: $-0.52
6 analysts 0y $-2.50
Lo: $-2.57 Hi: $-2.31
6 analysts +1y $-2.81
Lo: $-3.45 Hi: $-1.95
6 analysts +1q $-0.65
Lo: $-0.77 Hi: $-0.55
6 analysts ▲1
Cross-Platform Signals
No cross-platform signals in the last 90 days